Abstract:Background Early intensive insulin therapy in patients with newly diagnosed type 2 diabetes might improve beta-cell function and result in extended glycaemic remissions. We did a multicentre, randomised trial to compare the effects of transient intensive insulin therapy (continuous subcutaneous insulin infusion [CSII] or multiple daily insulin injections [MDI]) with oral hypoglycaemic agents on beta-cell function and diabetes remission rate.Methods 382 patients, aged 25-70 years, were enrolled from nine centres in China between September, 2004, and October, 2006. The patients, with fasting plasma glucose of 7.0-16.7 mmol/L, were randomly assigned to therapy with insulin (CSII or MDI) or oral hypoglycaemic agents for initial rapid correction of hyperglycaemia. Treatment was stopped after normoglycaemia was maintained for 2 weeks. Patients were then followed-up on diet and exercise alone. Intravenous glucose tolerance tests were done and blood glucose, insulin, and proinsulin were measured before and after therapy withdrawal and at 1-year follow-up. Primary endpoint was time of glycaemic remission and remission rate at 1 year after short-term intensive therapy. Analysis was per protocol. This study was registered with ClinicalTrials.gov, number NCT00147836.Findings More patients achieved target glycaemic control in the insulin groups (97.1% [133 of 137] in CSII and 95.2% [118 of 124] in MDI) in less time (4. 0 days [SD 2.51 in CSII and 5.6 days [SD 3.8] in MDI) than those treated with oral hypoglycaemic agents (83.5% [101 of 1211 and 9.3 days [SD 5.31). Remission rates after 1 year were significantly higher in the insulin groups (51. 1% in CSII and 44.9% in MDI) than in the oral hypoglycaemic agents group (26.7%; p=0.0012). beta-cell function represented by HOMA B and acute insulin response improved significantly after intensive interventions. The increase in acute insulin response was sustained in the insulin groups but significantly declined in the oral hypoglycaemic agents group at 1 year in all patients in the remission group.Interpretation Early intensive insulin therapy in patients with newly diagnosed type 2 diabetes has favourable outcomes on recovery and maintenance of beta-cell function and protracted glycaemic remission compared with treatment with oral hypoglycaernic agents.Funding 973 Programme from the Chinese Government, the Natural Science Foundation of Guangdong Province Government, Novo Nordisk (China), and Roche Diagnostics (Shanghai).

The relationship between first-phase insulin secretion and the therapeutic regimen in type 2 diabetes mellitus

Relationship Between Early–phase Insulin Secretion and Blood Glucose Variability in Subject with Normal Glucose Regulation

Relationship Between Initial Insulin Dosage and the Metabolic Parameters in Patients with Type 2 Diabetes

[The Effects of Early Intensive Therapy on Islet Beta Cell Function and Long-Term Glycemia Control in Newly Diagnosed Type 2 Diabetic Patients with Different Fasting Plasma Glucose Levels.].

1032-P: Time-in-Range during Short-Term Intensive Insulin Therapy Is Associated with Clinical Outcomes in Patients with Newly Diagnosed Type 2 Diabetes

PDG8 EFFICACY OF PHARMACOLOGICAL MONOTHERAPIES FOR TYPE 2 DIABETES IN CHINA

Relationship between Plasma Phospholipid Fatty Acid Profile and Insulin Resistance in Type 2 Diabetics

Relationships between metabolic parameters and islet function in type 2 diabetes complicated with fatty liver disease patients with different duration

Analysis of Insulin Doses of Chinese Type 2 Diabetic Patients with Intensive Insulin Treatment.

Effect of Intensive Insulin Therapy on Β-Cell Function and Glycaemic Control in Patients with Newly Diagnosed Type 2 Diabetes: a Multicentre Randomised Parallel-Group Trial

The Clinical Outcome of Early Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes

Analysis of the insulin dosage and impact factors of intensive insulin treatment of type 2 diabetic patients

Effect of regular intensive therapy with insulin pump on beta cell function in newly diagnosed type 2 diabetes mellitus

Exploring the influencing factors of non-insulin drug prescriptions in discharged patients with type 1 diabetes

[Influence of Short-Term Intensive Insulin Therapy on Plasma Concentration of Lipoprotein-Associated Phospholipase A(2) and Secretory Phospholipase A(2) in Newly Diagnosed Type 2 Diabetic Patients].

[Features of Insulin Secretion and Insulin Resistance in Newly Diagnosed Type 2 Diabetes of Different Body Mass Indices].

The value of arginine stimulation test in evaluating the first-phase insulin secretion and its guiding role for the treatment of type 2 diabetes mellitus

Differences in early-phase insulin secretion and glucose disposition index between aged and middle-aged patients with newly diagnosed type 2 diabetes

Survey of Glycemic Control in Type 2 Diabetic Patients Treated with Human Insulin in China

Efficacy Observation of the Intensivetherapy of Short-acting Insulin for 32 Patients with Type 2 Diabetes

Cross-sectional Study of the Pathophysiologic and Clinical Features in the First-Degree Relatives of Type 2 Diabetic Patients